Abstract
Breast cancer remains a significant concern worldwide, with a rising incidence in Indonesia. This study aims to evaluate the applicability of risk-based screening approaches in the Indonesian demographic through a case-control study involving 305 women. We developed a personalized breast cancer risk assessment workflow that integrates multiple risk factors, including clinical (Gail) and polygenic (Mavaddat) risk predictions, into a consolidated risk category. By evaluating the area under the receiver operating characteristic curve (AUC) of each single-factor risk model, we demonstrate that they retain their predictive accuracy in the Indonesian context (AUC for clinical risk: 0.67 [0.61,0.74]; AUC for genetic risk: 0.67 [0.61,0.73]). Notably, our combined risk approach enhanced the AUC to 0.70 [0.64,0.76], highlighting the advantages of a multifaceted model. Our findings demonstrate for the first time the applicability of the Mavaddat and Gail models to Indonesian populations, and show that within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.
Competing Interest Statement
The authors are affiliated with their respective organizations. BR, SGT, KNR, JA, FA, EAF, MGP, MDV, JH, LHU, YM, KIJ, MA, GG, FS, AF, SSM, LS and AI are affiliated with NalaGenetics. NalaGenetics is a biotech company focusing on personalized medications, diet, and screening. The risk prediction tool investigated in the study was developed by NalaGenetics. FAA, MW, STBS, AW, AS and SJH are affiliated with SJH Initiatives. SJH Initiatives is a research body under MRCCC Siloam Hospitals network whose one of the main focuses is on breast cancer research. SA is affiliated with Atma Jaya Catholic University of Indonesia. Atma Jaya is a private Catholic university based in Jakarta, Indonesia. The authors have no financial gain or loss in any form that could result from the publication of this manuscript, but the absence of authors without any organizational affiliation could be considered a non-financial competing interest.
Funding Statement
This study was funded by Nalagenetics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical & Health Research Ethics Commission of MRCCC Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* joint first authors
A revision has been implemented to enhance the depth of the analysis by integrating discussions concerning pathogenic mutations in BRCA1/2 genes, which serve as exemplary instances of monogenic risk. Additionally, minor textual modifications have been executed, and supplementary references have been included within the document to fortify the research findings.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
